Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 1589–1594 | Cite as

RETRACTED ARTICLE: Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy

  • Jinming Huang
  • Jiaoyuan Jia
  • Qiang Tong
  • Jun Liu
  • Jun Qiu
  • Rong Sun
  • Lixin Yao
  • Chun Yang
Research Article

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that can stabilize some proteins by inhibiting degradation mediated by protein phosphatase 2A (PP2A), and its level in cancer is associated with resistance to chemotherapy. However, whether CIP2A could increase chemoresistance of prostate cancer (PCa) cells to chemotherapeutic agent cabazitaxel remains unclear. To determine whether CIP2A serves as a potential therapeutic target of human PCa, we utilized small interference RNA (siRNA) to knock down CIP2A expression in human PCa cells and analyzed their phenotypic changes. The data demonstrated that CIP2A was significantly elevated in mCRPC cell lines C4-2 and ARCaPM at both the mRNA and protein levels. CIP2A silencing led to decreased proliferation and enhanced chemosensitivity and apoptosis to cabazitaxel in human PCa cells, as well as reduced Akt phosphorylation. Our data suggesting critical roles of CIP2A in PCa cells chemoresistance to cabazitaxel and raising the possibility of CIP2A inhibition as a promising approach for chemosensitization of metastatic castration-resistant prostate cancer (mCRPC).

Keywords

Prostate cancer Cancerous inhibitor of protein phosphatase 2A Cabazitaxel Small interfering RNA Proliferation Chemoresistance 

Notes

Acknowledgments

This study was supported by the grants from the National Natural Science Foundation of China (No. 81202036, 31471033)

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168(1):9–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014;6(4):167–79.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lassi K, Dawson NA. Update on castrate-resistant prostate cancer. Curr Opin Oncol. 2010;22:263–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Tannock I, De Wit R, Berry W, Horti J, Pluzanska A, Chi K, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Singh P, Yam M, Russell PJ, Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett. 2010;293:1–14.CrossRefPubMedGoogle Scholar
  8. 8.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res. 2014;20(12):3057–63.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257–66.CrossRefPubMedGoogle Scholar
  12. 12.
    Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 2011;585:755–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577–81.PubMedGoogle Scholar
  14. 14.
    Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene. 2007;26(35):5070–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55(5):300–18. quiz 305-323.CrossRefPubMedGoogle Scholar
  16. 16.
    Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 2013;15(1):110–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29(27):3686–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol. 2012;37(3):289–96.CrossRefGoogle Scholar
  20. 20.
    Kao SC, Hovey E, Marx G. Second-line therapy for castrate-resistant prostate cancer: a literature review. Asia Pac J Clin Oncol. 2011;7(3):212–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Lheureux S, Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer. 2012;99(9):875–80.PubMedGoogle Scholar
  22. 22.
    Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A, et al. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013;73(15):1681–9.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Urology85 Hospital of PLAShanghaiChina
  2. 2.Department of Oncology and Hematology, The Second HospitalJilin UniversityChangchunChina
  3. 3.Department of UrologyWuxi No.2 People’s Hospital affiliated to Nanjing Medical UniversityJiangsuChina

Personalised recommendations